NCT00001502 is a Phase 1 clinical trial of RMP-7 and carboplatin in Brain Neoplasms, sponsored by National Cancer Institute (NCI).

Who is sponsoring NCT00001502?

NCT00001502 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT00001502?

Interventions in NCT00001502: RMP-7 and carboplatin.

What condition does NCT00001502 study?

NCT00001502 studies Brain Neoplasms, Glioma, Medulloblastoma.

Is NCT00001502 still recruiting?

NCT00001502 is currently completed. Last updated 3 March 2008.

Last reviewed 2008-03-03 · How we verify

NCT00001502

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors

Completed Phase 1 Last updated 3 March 2008

What this trial tests

Phase 1 trial testing RMP-7 and carboplatin in Brain Neoplasms in 30 participants. Completed in 1 March 2000.

Timeline

1 April 1996

1 March 2000

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Enrollment	30
Start date	1 April 1996
Estimated completion	1 March 2000
Sites	1 location across United States

Drugs / interventions tested

RMP-7 and carboplatin — full drug profile →

Conditions studied

Brain Neoplasms — all drugs for Brain Neoplasms →
Glioma — all drugs for Glioma →
Medulloblastoma — all drugs for Medulloblastoma →

Sponsor

National Cancer Institute (NCI)

Who can join

Eligibility, any sex, with Brain Neoplasms or Glioma. Healthy volunteers can join.

Sponsor's own description

The presence of a highly selective blood-brain barrier (BBB) at the level of the brain capillary endothelium prevents chemotherapeutic agents from attaining therapeutic concentrations at the target site. RMP-7 is a synthetic bradykinin analog which specifically binds to B2 receptors expressed on the brain capillary endothelial cells and preferentially increases capillary permeability within CNS tumors. Carboplatin is an anticancer agent with preclinical and clinical antitumor activity against a variety of brain tumors. A pediatric phase I trial of the combination of RMP-7 and carboplatin will be conducted to determine the maximum tolerated dose of RMP-7 in children with refractory brain tumors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.
Nhàn NTT, Yamada T, Yamada KH. · · 2023 · cited 63× · PMID 37629112 · DOI 10.3390/ijms241612931
IL-17 Receptor Signaling Negatively Regulates the Development of Tubulointerstitial Fibrosis in the Kidney.
Ramani K, Tan RJ, Zhou D, Coleman BM, et al · · 2018 · cited 24× · PMID 30405320 · DOI 10.1155/2018/5103672

Verify or expand the search:

Other recruiting trials for Brain Neoplasms

Currently open trials in the same condition.

NCT07272616 — Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison · recruiting
NCT07426848 — OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients · NA · recruiting
NCT07111182 — Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery · NA · recruiting
NCT07238322 — [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes · active not recruiting
NCT06165653 — Guided Meditation During Radiation Therapy for Brain Tumors · NA · recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00001502 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 3 March 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00001502.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing